Hester Biosciences Limited — Updates, 01-08-2025: Press Release

Hester Biosciences released its Q1 financial results. Standalone divisional sales declined 14%, with profit down 7%. This was primarily due to a 33% sales drop in Animal Healthcare from delayed government immunization programs, though these are expected later. Poultry Healthcare grew 2%. Consolidated results impressed with 2% sales growth and a significant 131% jump in net profit to 17.30 Cr. This boost stems from Hester Africa's strong turnaround, swinging from a 5.00 Cr loss to a 5.50 Cr profit. Future plans include an Avian Influenza vaccine launch, animal healthcare diversification, and scaling African operations.